Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cocrystal Pharma, Inc.COCP · Entity 7621 | Director | January 09, 2026 | January 13, 2026 |
| Xenetic Biosciences, Inc.XBIO · Entity 8008 | Director | December 31, 2025 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cocrystal Pharma, Inc.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2036-01-09 | Direct | 24,615 |
Reported balance
After 2026-01-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 24,615 · Balance 24,615 F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date.
Xenetic Biosciences, Inc.
Report date December 31, 2025 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.17 · Expires 2035-12-31 | Direct | 2,500 |
Reported balance
After 2025-12-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-31 · Grant · Acquired 2,500 · Balance 2,500 F1: The Options vest 100% on the twelve-month anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Options vest 100% on the twelve-month anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2026 Filed Jan 13, 2026 17:03 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 24,615 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001683168-26-000263 · ownership.xml · derivative · entry 1 Kornberg Roger D. · CIK 0001444532 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,615 Underlying: Common Stock · 24,615 shares Expires 2036-01-09 F1 · security: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date. F1 · derivative.exercise_date: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 17:00 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 2,500 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0001683168-26-000102 · ownership.xml · derivative · entry 1 Kornberg Roger D. · CIK 0001444532 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2035-12-31 F1 · derivative.exercise_date: The Options vest 100% on the twelve-month anniversary of the grant date. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 17:00 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 2,500 | $0.00 Strike: $4.24 | $0.00 |
DisclosureSEC source: 0001683168-24-008720 · ownership.xml · derivative · entry 1 Kornberg Roger D. · CIK 0001444532 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2034-12-11 F1 · derivative.exercise_date: The Options vest 100% on the twelve-month anniversary of the grant date. Read SEC document |
| October 09, 2024 Filed Oct 11, 2024 16:06 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantCommon Stock | 28,109 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-040903 · ownership.xml · nonDerivative · entry 1 Kornberg Roger D. · CIK 0001444532 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,109 F1 · security: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan. F1 · price: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 17:30 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 2,500 | $0.00 Strike: $4.29 | $0.00 |
DisclosureSEC source: 0001683168-23-008740 · ownership.xml · derivative · entry 1 Kornberg Roger D. · CIK 0001444532 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2033-12-06 F1 · derivative.exercise_date: The Options vest 100% on the twelve-month anniversary of the grant date. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 16:05 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 24,417 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001493152-23-025083 · ownership.xml · derivative · entry 1 Kornberg Roger D. · CIK 0001444532 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,417 Underlying: Common Stock · 24,417 shares Expires 2033-07-18 F1 · derivative.exercise_date: The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 18, 2024 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2024, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 17:03 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0001683168-22-008323 · ownership.xml · derivative · entry 1 Kornberg Roger D. · CIK 0001444532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-12-07 F1 · derivative.exercise_date: The Options vest 100% on the twelve-month anniversary of the grant date. Read SEC document |
| July 25, 2022 Filed Aug 3, 2022 16:02 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 280,000 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001493152-22-021147 · ownership.xml · derivative · entry 1 Kornberg Roger D. · CIK 0001444532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2032-07-25 F1 · derivative.exercise_date: The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 25, 2023 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2023, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 17:40 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001683168-21-006230 · ownership.xml · derivative · entry 1 Kornberg Roger D. · CIK 0001444532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-12-07 F1 · derivative.exercise_date: The Options vest 100% on the twelve-month anniversary of the grant date. Read SEC document |
| July 16, 2021 Filed Jul 20, 2021 16:06 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001493152-21-017328 · ownership.xml · derivative · entry 1 Kornberg Roger D. · CIK 0001444532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2031-07-16 F1 · derivative.exercise_date: The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 16, 2022 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2022, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 17:03 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001683168-20-004205 · ownership.xml · derivative · entry 1 Kornberg Roger D. · CIK 0001444532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-12-04 F1 · derivative.exercise_date: The Options vest 100% on the twelve-month anniversary of the grant date. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 16:54 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001493152-20-011730 · ownership.xml · derivative · entry 1 Kornberg Roger D. · CIK 0001444532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-06-22 F1 · derivative.exercise_date: The stock options vest as follows: 25,000 stock options will vest on the one year anniversary of the grant date and the remaining 25,000 stock options will vest in eight equal quarterly increments with the first such quarterly increment vesting on September 30, 2021. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 18:33 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001683168-19-003917 · ownership.xml · derivative · entry 1 Kornberg Roger D. · CIK 0001444532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-12-04 F1 · derivative.exercise_date: The Options vest 100% on the twelve month anniversary of the grant date. Read SEC document |
| November 28, 2018 Filed Nov 30, 2018 17:22 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $3.05 | $0.00 |
DisclosureSEC source: 0001662252-18-000104 · ownership.xml · derivative · entry 1 Kornberg Roger D. · CIK 0001444532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-11-28 F1 · derivative.exercise_date: The Options vest in equal quarterly installments over the twelve-month period commencing on the grant date. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 17:34 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Option · Derivative | 25,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001662252-17-000230 · form4.xml · derivative · entry 1 Kornberg Roger D. · CIK 0001444532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-11-15 F1 · derivative.exercise_date: On November 15, 2017 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its Amended and Restated 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 25,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on November 15, 2017 of $2.18. The Option vests one-quarter of the total grant for each quarter of service over the twelve-month period commencing on the grant date. Read SEC document |
| December 20, 2016 Filed Dec 23, 2016 14:09 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Option · Derivative | 21,970 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001662252-16-000303 · form4.xml · derivative · entry 2 Kornberg Roger D. · CIK 0001444532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 21,970 shares Expires 2026-12-20 F2 · price: On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 21,970 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.50. Read SEC document |
| December 20, 2016 Filed Dec 23, 2016 14:09 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Option · Derivative | 3,030 | $0.00 Strike: $10.23 | $0.00 |
DisclosureSEC source: 0001662252-16-000303 · form4.xml · derivative · entry 1 Kornberg Roger D. · CIK 0001444532 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,030 Underlying: Common Stock · 3,030 shares Expires 2026-02-28 F1 · price: On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The grant had been approved and was part of an agreement (but not issued) on the date of the Reporting Owner began service as a director of the Issuer. Under the agreement and grant, the Reporting Owner has the right to purchase 3,030 shares of common stock of the Issuer under the Plan at an exercise price based on the adjusted price of the stock on the date of his appointment to the board. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.